Sequential Docetaxel Research Articles

Promising clinical and pathological response rates with neoadjuvant sequential doxorubicine (DOX) and docetaxel (DOC) in locally advanced breast cancer (LABC)

Promising clinical and pathological response rates with neoadjuvant sequential doxorubicine (DOX) and docetaxel (DOC) in locally advanced breast cancer (LABC)

Sequential docetaxel and vinorelbine for patients with advanced breast cancer previously treated with anthracyclines: A phase II study

With respect to their association, sequential non-cross-resistant cytostatics could be better tolerated and allow a similar antitumor effect. From January, 1998 to July, 1999, 42 consecutive patients with metastatic breast cancer (MBC) previously treated with anthracyclines as adjuvant- or first-line therapy entered a phase II multicenter study where docetaxel (TXT, 100 mg/m2/3 weeks/4 times) was followed by vinorelbine (VNR, 25 mg/m2/10 days/8 times). Median follow-up is 21 months and 22/42 patients have died. Four patients did not complete therapy due to early death, grade 3-4 gastrointestinal mucosytis (2 patients) and grade 3 neurotoxicity during TXT therapy. Overall response rate was 57%, and 5% of patients had stable disease. There were 38% of therapy failures due to non-evaluability (10%) or progressive disease (28%). Median time to progression and survival are 10.1 and 17.1 months. Sequential TXT-VNB is a suitable strategy for MBC patients previously treated with anthracyclines. It avoids haematologic toxicity and allows a good antitumor effect. Careful monitoring of intestinal mucosytis is required.

Successful chemo-endocrine therapy for multiple bone metastases and myelophthisis caused by occult breast carcinoma

We report a 55-year-old postmenopausal woman with occult breast carcinoma with multiple bone metastases and myelophthisis in whom complete response (CR) was achieved with chemo-endocrine therapy. At the time of admission, she had anemia and left axillary lymph node enlargement, with extremely high levels of serum tumor markers and no breast mass on physical examination or on a mammogram. Roentgenograms and bone scintigrams showed multiple bone, lung, and pleural metastases. Bone marrow biopsy and aspiration cytology from the left axillary lymph node revealed an invasion of adenocarcinoma cells. On immunohistochemical staining, the cancer cells were positive for estrogen receptor (ER), progesterone receptor (PgR), and gross cystic disease fluid protein-15 (GCDFP-15). CR was induced with a combination chemotherapy of doxorubicin, cyclophosphamide, and 5-fluorouracil (CAF), and has been maintained with sequential docetaxel administration with endocrine therapy. Her performance status (Eastern Cooperative Oncology Group) improved from 4 to 0. This patient represents a very specific and rare case in whom a primary tumor could not be detected despite severe advanced breast carcinoma, and in whom CR was achieved by chemo-endocrine therapy.

Locally advanced breast cancer (LABC): neoadjuvant chemotherapy with sequential doxorubicine (DOX) and docetaxel (DOC)

Locally advanced breast cancer (LABC): neoadjuvant chemotherapy with sequential doxorubicine (DOX) and docetaxel (DOC)

Phase II study of sequential docetaxel (Taxotere®, TXT) and doxorubicin (Dox) as primary chemotherapy (CT) for large operable breast cancer (BC)

Phase II study of sequential docetaxel (Taxotere®, TXT) and doxorubicin (Dox) as primary chemotherapy (CT) for large operable breast cancer (BC)

Sequential doxorubicine (DOX) and docetaxel (DOC) as neoadjuvant chemotherapy in locally advanced breast cancer (LABC): A pilot study

Sequential doxorubicine (DOX) and docetaxel (DOC) as neoadjuvant chemotherapy in locally advanced breast cancer (LABC): A pilot study